PDE10A and prostate cancer: 15 have reported that PDE10A mutations are predicted to influence PDE10A allosteric regulation in lung adenocarcinoma; that high levels of PDE10A expression correlate with worsened lung adenocarcinoma prognosis; and that Pf‐2545920 also suppresses the growth of NSCLC cell lines. Finally, PDE10A somatic mutations have been described in up to 19% of prostate cancers and correlated with increased levels of phosphorylated C‐AMP responsive element binding protein (p‐CREB) 24.